(Q36505767)

14 August 2017

1 reference

title

Epigenetics of lung cancer (English)

1 reference

14 August 2017

1 reference

1 reference

Rayleen V Bowman

1

1 reference

14 August 2017

Ian A Yang

series ordinal

2

1 reference

14 August 2017

Annalese B T Semmler

series ordinal

3

1 reference

14 August 2017

Kwun M Fong

series ordinal

4

1 reference

14 August 2017

publication date

1 July 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

11

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

355-365

1 reference

The impact of tobacco on lung health in China

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Tumorigenesis: the adaptation of mammalian cells to sustained stress environment by epigenetic alterations and succeeding matched mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Worms gang up on bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Glycosylation regulates Notch signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Targeting the epigenome for the treatment and prevention of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

The history of cancer epigenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Epigenetics in lung cancer: focus on progression and early lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Life-span inhalation exposure to mainstream cigarette smoke induces lung cancer in B6C3F1 mice through genetic and epigenetic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Aberrant methylation of SPARC in human lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Gene-promoter hypermethylation as a biomarker in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

The power and the promise of DNA methylation markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Diagnostic and therapeutic applications of epigenetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Gene promoter methylation in plasma and sputum increases with lung cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Cellular differentiation, cytidine analogs and DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Aberrant CpG-island methylation has non-random and tumour-type-specific patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Antineoplastic action of 5-aza-2'-deoxycytidine and phenylbutyrate on human lung carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Human DNA methyltransferase 1 is required for maintenance of the histone H3 modification pattern

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

High-performance capillary electrophoretic method for the quantification of 5-methyl 2'-deoxycytidine in genomic DNA: application to plant, animal and human cancer tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Induction of DNA methylation and gene silencing by short interfering RNAs in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Small interfering RNA-induced transcriptional gene silencing in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Histone deacetylases (HDACs): characterization of the classical HDAC family

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Class II histone deacetylases: from sequence to function, regulation, and clinical implication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Prospects: histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Regulation of histone deacetylase activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

High-throughput screening of genome fragments bound to differentially acetylated histones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Histone deacetylase 1 mRNA expression in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Decreased histone deacetylase activity in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

No association between polymorphisms in the histone deacetylase genes and the risk of lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Nuclear levels and patterns of histone H3 modification and HP1 proteins after inhibition of histone deacetylases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Effects of the histone deacetylase inhibitor trichostatin A on nuclear texture and c-jun gene expression in drug-sensitive and drug-resistant human H69 lung carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein kinase C inhibitor (calphostin C).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Estimates of global mortality attributable to smoking in 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Promoter Methylation and Silencing of the Retinoic Acid Receptor- Gene in Lung Carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

Studies of X chromosome DNA methylation in normal human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1843.2006.00859.X

10.1111/J.1440-1843.2006.00859.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference